世界各国のリアルタイムなデータ・インテリジェンスで皆様をお手伝い



世界のてんかん治療薬市場 2018-2022年

Global Epilepsy Drugs Market 2018-2022

IRTNTR21967

 

出版社 出版日電子媒体価格ページ数
TechNavio
テクナビオ
2018年9月 US$ 2,500
シングルユーザライセンス
112p

サマリー

この調査レポートは世界のてんかん治療薬市場を分析・予測したTechNavioの市場調査報告書です。

Description

About Epilepsy Drugs
Epilepsy is a neurological disorder characterized by episodes of abnormally increased neuronal discharge resulting in transient episodes of sensory or motor neurological dysfunction or psychic dysfunction.
Technavio’s analysts forecast the Global Epilepsy Drugs Market to grow at a CAGR of 7.19% during the period 2018-2022.

Covered in this report
The report covers the present scenario and the growth prospects of the epilepsy drugs market. To calculate the market size, the report considers the revenue generated by sales of epilepsy drugs across the globe.

The market is divided into the following segments based on geography:
? Americas
? APAC
? EMEA

Technavio's report, epilepsy drugs market 2018-2022, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors
? Eisai
? GlaxoSmithKline
? Novartis
? Pfizer
Market driver
? Advances in understanding of epilepsy pathology
? For a full, detailed list, view our report

Market challenge
? Low safety profile of AEDs
? For a full, detailed list, view our report

Market trend
? Increasing costs of epilepsy management
? For a full, detailed list, view our report

Key questions answered in this report
- What will the market size be in 2022 and what will the growth rate be?
- What are the key market trends?
- What is driving this market?
- What are the challenges to market growth?
- Who are the key vendors in this market space?
- What are the market opportunities and threats faced by the key vendors?
- What are the strengths and weaknesses of the key vendors-

You can request one free hour of our analyst’s time when you purchase this market report. Details are provided within the report.



目次

PART 01: EXECUTIVE SUMMARY
PART 02: SCOPE OF THE REPORT
PART 03: RESEARCH METHODOLOGY
PART 04: MARKET LANDSCAPE
? Market ecosystem
? Market characteristics
? Market segmentation analysis
PART 05: PIPELINE ANALYSIS
? Unmet needs of available AEDs
? Pipeline drugs for epilepsy
PART 06: MARKET SIZING
? Market definition
PART 07: MARKET SIZING 2017
? Market definition
? Market size and forecast 2017-2022
PART 08: FIVE FORCES ANALYSIS
? Bargaining power of buyers
? Bargaining power of suppliers
? Threat of new entrants
? Threat of substitutes
? Threat of rivalry
? Market condition
PART 09: MARKET SEGMENTATION BY DRUG ACTIVITY SPECTRUM
? Segmentation by drug activity spectrum
? Comparison by drug activity spectrum
? Narrow spectrum drugs - Market size and forecast 2017-2022
? Broad spectrum drugs - Market size and forecast 2017-2022
? Market opportunity by drug activity spectrum
PART 10: MARKET SEGMENTATION BY ETIOLOGY
? Segmentation by etiology
PART 11: MARKET SEGMENTATION BY AGE OF ONSET
? Segmentation by age of onset
PART 12: CUSTOMER LANDSCAPE
PART 13: REGIONAL LANDSCAPE
? Geographical segmentation
? Regional comparison
? Americas - Market size and forecast 2017-2022
? EMEA - Market size and forecast 2017-2022
? APAC - Market size and forecast 2017-2022
? Market opportunity
PART 14: DECISION FRAMEWORK
PART 15: DRIVERS AND CHALLENGES
? Market drivers
? Market challenges
PART 16: MARKET TRENDS
? Increase in epilepsy management costs
? Use of immunotherapy and immunomodulators
? Use of genetics as therapeutics and diagnostic modality
? Research in precision healthcare infrastructure
PART 17: VENDOR LANDSCAPE
? Overview
? Landscape disruption
PART 18: VENDOR ANALYSIS
? Vendors covered
? Vendor classification
? Market positioning of vendors
? Eisai
? GlaxoSmithKline
? Novartis
? Pfizer
PART 19: APPENDIX
? List of abbreviations

?

?
Exhibit 01: Parent market
Exhibit 02: Global CNS disorders therapeutics market
Exhibit 03: Market characteristics
Exhibit 04: Market segments
Exhibit 05: Need, demand, and supply analysis of AEDs
Exhibit 06: Pipeline drugs under phase III development
Exhibit 07: Market definition - Inclusions and exclusions checklist
Exhibit 08: Market size 2017
Exhibit 09: Validation techniques employed for market sizing 2017
Exhibit 10: Global epilepsy drugs market - Market size and forecast 2017-2022 ($ bn)
Exhibit 11: Global epilepsy drugs market - Year over year growth 2018-2022 (%)
Exhibit 12: Five forces analysis 2017
Exhibit 13: Five forces analysis 2022
Exhibit 14: Bargaining power of buyers
Exhibit 15: Bargaining power of suppliers
Exhibit 16: Threat of new entrants
Exhibit 17: Threat of substitutes
Exhibit 18: Threat of rivalry
Exhibit 19: Market condition - Five forces 2017
Exhibit 20: Global epilepsy drugs market by drug activity spectrum - Market share 2017-2022 (%)
Exhibit 21: Comparison by drug activity spectrum
Exhibit 22: Global epilepsy drugs market by narrow spectrum drugs - Market size and forecast 2017-2022 ($ bn)
Exhibit 23: Global epilepsy drugs market by narrow spectrum drugs - Year over year growth 2018-2022 (%)
Exhibit 24: Global epilepsy drugs market by broad spectrum drugs - Market size and forecast 2017-2022 ($ bn)
Exhibit 25: Global epilepsy drugs market by broad spectrum drugs - Year over year growth 2018-2022 (%)
Exhibit 26: Market opportunity by drug activity spectrum
Exhibit 27: Customer Landscape
Exhibit 28: Global epilepsy drugs market by region - Market share 2017-2022 (%)
Exhibit 29: Regional comparison
Exhibit 30: Epilepsy drugs market in Americas - Market size and forecast 2017-2022 ($ bn)
Exhibit 31: Epilepsy drugs market in Americas - Year over year growth 2018-2022 (%)
Exhibit 32: Top three countries in Americas
Exhibit 33: Epilepsy drugs market in EMEA - Market size and forecast 2017-2022 ($ bn)
Exhibit 34: Epilepsy drugs market in EMEA - Year over year growth 2018-2022 (%)
Exhibit 35: Top three countries in EMEA
Exhibit 36: Epilepsy drugs market in APAC - Market size and forecast 2017-2022 ($ bn)
Exhibit 37: Epilepsy drugs market in APAC - Year over year growth 2018-2022 (%)
Exhibit 38: Top three countries in APAC
Exhibit 39: Market opportunity
Exhibit 40: Examples of epilepsy drugs discontinued due to safety issues:
Exhibit 41: Epilepsy management costs
Exhibit 42: Price of leading branded AEDs
Exhibit 43: Vendor landscape
Exhibit 44: Landscape disruption
Exhibit 45: Vendors covered
Exhibit 46: Vendor classification
Exhibit 47: Market positioning of vendors
Exhibit 48: Eisai overview
Exhibit 49: Eisai - Business segments
Exhibit 50: Eisai - Organizational developments
Exhibit 51: Eisai - Geographic focus
Exhibit 52: Eisai - Segment focus
Exhibit 53: Eisai - Key offerings
Exhibit 54: GlaxoSmithKline overview
Exhibit 55: GlaxoSmithKline - Business segments
Exhibit 56: GlaxoSmithKline - Organizational developments
Exhibit 57: GlaxoSmithKline - Geographic focus
Exhibit 58: GlaxoSmithKline - Segment focus
Exhibit 59: GlaxoSmithKline - Key offerings
Exhibit 60: Novartis overview
Exhibit 61: Novartis - Business segments
Exhibit 62: Novartis - Organizational developments
Exhibit 63: Novartis - Geographic focus
Exhibit 64: Novartis - Segment focus
Exhibit 65: Novartis - Key offerings
Exhibit 66: Pfizer overview
Exhibit 67: Pfizer - Business segments
Exhibit 68: Pfizer - Organizational developments
Exhibit 69: Pfizer - Geographic focus
Exhibit 70: Pfizer - Segment focus
Exhibit 71: Pfizer - Key offerings

 

COPYRIGHT(C) 2011-2019 DATA RESOURCES, Inc. ALL RIGHTS RESERVED.